AI Article Synopsis
- A study using data from the 2013 National Health and Wellness Survey compared the experiences of women using extended-cycle combined oral contraception (COC) with those using monthly-cycle COC, focusing on factors such as treatment satisfaction and menstrual symptoms.
- Women on extended-cycle COC reported higher treatment satisfaction and adherence, as well as less heavy menstrual bleeding, but also experienced more health issues and related symptoms like fatigue and headaches.
- Overall, the findings suggest that while extended-cycle COC may offer benefits like reduced menstrual symptoms, it is often prescribed to women with pre-existing health problems.
Article Abstract
Background: The real-world experience of women receiving extended-cycle combined oral contraception (COC) versus monthly-cycle COC has not been reported.
Methods: Data were from the United States 2013 National Health and Wellness Survey. Eligible women (18-50 years old, premenopausal, without hysterectomy) currently using extended-cycle COC (3 months between periods) were compared with women using monthly-cycle COC. Treatment satisfaction (1 "extremely dissatisfied" to 7 "extremely satisfied"), adherence (8-item Morisky Medication Adherence Scale), menstrual cycle-related symptoms, health-related quality of life (HRQOL) and health state utilities (Medical Outcomes Short Form Survey-36v2®), depression (9-item Patient Health Questionnaire), sleep difficulties, Work Productivity and Activity Impairment-General Health, and healthcare resource use were assessed using one-way analyses of variance, chi-square tests, and generalized linear models (adjusted for covariates).
Results: Participants included 260 (6.7%) women using extended-cycle and 3616 (93.3%) using monthly-cycle COC. Women using extended-cycle COC reported significantly higher treatment satisfaction (P = 0.001) and adherence (P = 0.04) and reduced heavy menstrual bleeding (P = 0.029). A non-significant tendency toward reduced menstrual pain (39.5% versus 47.3%) and menstrual cycle-related symptoms (40.0% versus 48.7%) was found in women using extended-cycle versus monthly-cycle COC. Significantly more women using extended-cycle COC reported health-related diagnoses, indicating preferential prescription for extended-cycle COC among women reporting more health problems. Consistent with this poorer health, more women using extended-cycle COC reported fatigue, headache, and activity impairment (P values < 0.05). There were no other significant differences between groups.
Conclusions: This real-world observational study supports extended-cycle COC as a valuable treatment option with high satisfaction, high adherence, and reduced heavy menstrual bleeding.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774154 | PMC |
| http://dx.doi.org/10.1186/s12905-017-0508-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synergistic effect of oxygen vacancies and in-situ formed bismuth metal centers on BiVO as an enhanced bifunctional Li-O batteries electrocatalyst.
J Colloid Interface Sci
January 2025
Department of Chemistry and Nanoscience, Division of Molecular and Life Sciences, College of Natural Sciences, Ewha Womans University, 52, Ewhayeodae-gil, Seodaemun-gu, Seoul 03760, Republic of Korea; Nanobio⋅Energy Materials Center (National Research Facilities and Equipment Center), Ewha Womans University, 52, Ewhayeodae-gil, Seodaemun-gu, Seoul 03760, Republic of Korea; Basic Sciences Research Institute, Ewha Womans University, 52, Ewhayeodae-gil, Seodaemun-gu, Seoul 03760, Republic of Korea. Electronic address:
Bismuth Vanadate (BiVO) is a promising oxide-based photoanode for electrochemical applications, yet its practical use is constrained by poor charge transport properties, particularly under dark conditions. This study introduces a novel BiVO variant (Bi-BiVO-10) that incorporates abundant oxygen vacancies and in-situ formed Bi metal, significantly enhancing its electrical conductivity and catalytic performance. Bi-BiVO-10 demonstrates superior electrochemical performances compared to conventional BiVO (C-BiVO), demonstrated by its most positive half-wave potential with the highest diffusion-limiting current in the oxygen reduction reaction (ORR) and earliest onset potential in the oxygen evolution reaction (OER).
View Article and Find Full Text PDFMenstrually associated migraine.
Handb Clin Neurol
February 2024
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy. Electronic address:
Menstrually related migraine is a disabling condition affecting 35% to 54% females with migraine during their fertile years. The International Headache Classification distinguishes menstrually related migraine from pure menstrual migraine based on the occurrence of the attacks even outside the perimenstrual periods. Hormonal fluctuations are the main driver for the disease in subjects with genetic susceptibility and alterations of brain structures and connectivity.
View Article and Find Full Text PDFOral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study.
Am J Obstet Gynecol
June 2022
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address:
Article Synopsis
- This study investigates the link between different types of oral contraceptives and breast cancer risk, particularly focusing on specific disease subtypes.
- The research, involving over 113,000 women, reveals that current use of oral contraceptives is associated with a higher risk of invasive breast cancer, especially for those using them for more than five years.
- The findings indicate that while current users have an increased risk, former users who have stopped for more than five years show similar risks to those who have never used contraceptives, and these associations don’t vary significantly by tumor subtype.
Extended-cycle versus conventional treatment with a combined oral contraceptive containing ethinylestradiol (30 μg) and levonorgestrel (150 μg) in a randomized controlled trial.
Gynecol Endocrinol
June 2020
VivaNeo Kinderwunschpraxis Frankfurt, Frankfurt am Main, Germany.
The objective was to assess efficacy and safety of a combined oral contraceptive containing ethinylestradiol (EE) and levonorgestrel (LNG) in an extended-cycle vs. a conventional-cycle regimen. This first European randomized, active controlled, open, prospective, parallel-group trial was conducted in 48 German gynecological centers.
View Article and Find Full Text PDFContraception counseling for women with premenstrual dysphoric disorder (PMDD): current perspectives.
Open Access J Contracept
September 2019
Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Premenstrual Dysphoric Disorder (PMDD) is a severe form of premenstrual syndrome (PMS) affecting up to 7% of reproductive age women. Women with PMDD are of reproductive age; therefore, contraception and treatment of PMDD are important considerations. The disorder as described in the DSM-V is characterized by moderate to severe psychological, behavioral and physical symptoms beginning up to two weeks prior to menses, resolving soon after the onset of menstruation and significantly interfering with daily functioning.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!